<SEC-DOCUMENT>0001493152-25-003148.txt : 20250122
<SEC-HEADER>0001493152-25-003148.hdr.sgml : 20250122
<ACCEPTANCE-DATETIME>20250122070026
ACCESSION NUMBER:		0001493152-25-003148
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20250122
FILED AS OF DATE:		20250122
DATE AS OF CHANGE:		20250122

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OKYO Pharma Ltd
		CENTRAL INDEX KEY:			0001849296
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41386
		FILM NUMBER:		25543869

	BUSINESS ADDRESS:	
		STREET 1:		55 PARK LANE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1K 1NA
		BUSINESS PHONE:		44 (0) 207 495 2379

	MAIL ADDRESS:	
		STREET 1:		55 PARK LANE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1K 1NA
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-k.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
6-K</B></FONT></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPORT
OF FOREIGN PRIVATE ISSUER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO RULE 13a-16 OR 15d-16</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>January
2025</B></FONT></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commission
File Number:</B> 001-41386</FONT></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>OKYO
Pharma LTD</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
Name of Registrant as Specified in Its Charter)</FONT></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>9<SUP>th
</SUP>Floor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>107
Cheapside</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>London
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>EC2V
6DN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of registrant&rsquo;s principal executive office)</FONT></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
20-F &#9746; Form 40-F &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION
CONTAINED IN THIS REPORT ON FORM 6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 22, 2025, OKYO Pharma LTD (the &ldquo;<U>Company</U>&rdquo;) issued this 6K announcing today, that it has received $1.4 million
in non-dilutive funding. This significant financial funding strengthens the Company&rsquo;s ability to advance its innovative pipeline
without diluting shareholder value. The funding will be strategically allocated to support ongoing research and development initiatives,
with particular emphasis on fueling progress with OKYO&rsquo;s lead program, OK-101 focused on treating NCP, a major unmet medical need.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being
furnished and shall not be deemed &ldquo;filed&rdquo; for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise
subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under
the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly
set forth by specific reference in such a filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OKYO
    Pharma LTD</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    January 22, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Keeren Shah</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keeren
    Shah</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
INDEX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex99-1.htm">Announcement, dated Janaury 22, 2025</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_001.jpg" ALT="" style="width:250px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OKYO
Pharma Receives $1.4 Million in Non-Dilutive Funding</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">London
and New York, NY, January 22, 2025. OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative
therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory
dry eye disease (DED), a multi-billion-dollar market, is pleased to announce that it has received $1.4 million in non-dilutive funding.
This significant financial funding strengthens the Company&rsquo;s ability to advance its innovative pipeline without diluting shareholder
value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
funding will be strategically allocated to support ongoing research and development initiatives, with particular emphasis on fueling
progress with OKYO&rsquo;s lead program, OK-101 focused on treating NCP, a major unmet medical need.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Securing
$1.4 million in non-dilutive funding marks an important milestone for OKYO Pharma. This financial boost will significantly contribute
to our mission of developing groundbreaking treatments for ophthalmic diseases,&rdquo; commented Dr. Gary S. Jacob, CEO of OKYO Pharma.
&ldquo;Importantly, this funding supports our ability to continue creating value for our shareholders while advancing our clinical programs.
We remain committed to driving innovation and delivering solutions that improve patient outcomes.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
infusion of non-dilutive funding underscores OKYO Pharma&rsquo;s commitment to maintaining fiscal responsibility while pursuing transformative
therapies that address critical unmet medical needs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
NCP</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuropathic
corneal pain (NCP) is a condition that causes pain and sensitivity of the eyes, face, or head. The exact cause of NCP is unknown but
thought to result from nerve damage to the cornea combined with inflammation. NCP, which can exhibit as a severe, chronic, or debilitating
condition in patients suffering from a host of ophthalmic conditions, is presently treated by various topical and systemic treatments
in an off-label fashion. Notably, there is no FDA approved drug to treat this debilitating condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; color: #1A1A1A"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
OK-101</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; color: #1A1A1A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OK-101
is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of
the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. OK-101 was developed
using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating dry eye disease. OK-101 has been
shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and corneal neuropathic pain (NCP),
respectively, and is designed to combat washout through the inclusion of the lipid anchor built into the drug molecule to potentially
enhance the residence time of OK-101 within the ocular environment. OK-101 showed clear statistical significance in multiple endpoints
in a recently completed Phase 2, multi-center, double-masked, placebo-controlled trial of OK-101 to treat DED, and is presently being
evaluated in <FONT STYLE="background-color: white">a randomized, placebo-controlled, double-masked Phase 2 trial to treat 48 NCP patients.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; color: #1A1A1A"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; color: #1A1A1A"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
OKYO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; color: #1A1A1A"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; color: #1A1A1A"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OKYO
Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of NCP
and DED, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel
molecules to treat NCP and inflammatory DED. In addition to the completed Phase 2 trial of OK-101 to treat DED patients, OKYO is also
currently evaluating OK-101 to treat NCP patients in a Phase 2 trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; color: #1A1A1A"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
further information, please visit <U>www.okyopharma.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Enquiries:</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OKYO
    Pharma Limited</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary
    S. Jacob, Chief Executive Officer</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">917-497-7560</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Business
    Development &amp; Investor Relations</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
    Spencer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+44
    (0)20 7495 2379</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection Last; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !Z A4# 2(  A$! Q$!_\0
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M7KH=%2IS4U)&1_PLCQA_T,%[_P!]U]"?"_4[W6/ =E>ZA<O<7+M(&D<Y)PQ
MKY2KZB^#O_)-=/\ ]^7_ -#-7BHQ4-$1AY-RU9WE%%%><=P5P/Q!^)MCX0@:
MSM2ESJ[K\L6<K%_M/_A6'\2/BW%HXETC0)%FO_NRW*G*P^P]6_E7S_<7$UU<
M23SR-)+(Q9W<Y+'U-=M##\WO3V.6K7MI$Z>3XE^,9)6D.O7:ECG"M@#Z#M1'
M\1/&<LBQQZ[?N['"JK9)/L*P-,TN]UB_BL=/MWGN)3A409__ %"OHWX??"VR
M\*1QW^H!+K5R,[L92'V7W]ZZ:LJ=-:HPIQG-[D?@SPSXMN=->[\3^(=1CEF3
M]S;1RX,6?XF/K[5YWXUOOB'X+U'R;G7KZ6TD)\BY5OE<>A]#[5]&U2U72;'6
M].EL-1MTGMI1AE8?J/0UPQK6E>2T.N5*\;)ZGRO_ ,+(\8?]#!>_]]UT7A#X
MQ:WI&IC^V[F74;"0XD#G+Q^ZG^E9_P 0?AK?>#KDW-N'N=)D;Y)@.8_]E_3V
M/>N$KT%&G4CHM#B<IPEJS[2TK5;+6M.BO]/N$GMI1E74_H?0U<KY*\%>.=3\
M&:D);9C+9R$>?:L?E<>H]#[U].>&O$^F>*M+2^TV<.IXDC)^>-O1A7G5J+IN
M_0[:5537F;-%%%8&P5!>WMMIUI)=WDZ06\2[GD<X %4M?\0Z;X:TN34-3N%B
MA7H/XG/HH[FOF?QW\0]2\9WA0EK?38V_<VRG]6]3_*MZ5%U'Y&52JH+S.C\<
M?&/4M2OS;^'9Y+*QB;B9>))CZ^P]JY/_ (61XP_Z&"]_[[KEJ]#^'?PQN_%L
MR7U\'MM(1N7QAIO9?;WKT7&G3CJCA4ISEHS5\#7'Q"\:7N8]?OK?3HV_?73-
MP/9?4UU_B7XPZ7X90Z5I DU:[@&QKB60E PZY/5CGTQ5SXH:G%X*^'T>F:/$
MMK]I/V:,1\;%QEC]<=_>OFSK6,(1J^\UH:SFZ?NIZGH=[\:?&-TQ\JZM[53V
MB@4X_%LFLB3XF>,9&R=>NQ_ND#^0KE "Q  ))Z 5K0>%M?NHQ)!H][(AZ%86
M_P *Z/9TX]$8\\WU-+_A9'C#_H8+W_ONC_A9'C#_ *&"]_[[JE_PAGB7_H!W
M_P#WX;_"C_A#/$O_ $ [_P#[\-_A2M3\OP"\_,N_\+(\8?\ 0P7O_?=/3XE^
M,8VR->NS_O,#_2L__A#/$O\ T [_ /[\-_A45QX6U^UC,D^CWL:#J6A;_"G:
MGY?@%Y^9U=G\:/&-J1YMY!<J/X98%Y_$8->C>$/C9IVL7$5EK5NMA<OP)E;,
M3-Z<\K^M?/!!4D$$$=0:2HE0IR6PXUIQZGVZ"& (((/((HKS3X-^*VUGPH]E
M?3%KC3W$8=S]Z,CY>?;!'X"BO+G!QDXL]&,E)71Z91114%!15>\OK73K5[F\
MGC@A3[SN< 5Y+XK^*\UT7LO#X:)#P;DCYV_W1V_G2;L=-##5*[M!?/H=YXG\
M<Z3X8C*32>?>8^6VB/S?B>U>)^)?&NK^)I2+F8Q6N?EMXCA1]?4_6K^B?#WQ
M!XCD^TS(;:%SEI[G.6SW ZFN]/@?PSX+T6?5-0C-_+"N09^A;L O3K4ZL]:F
ML+A6DO?G_7R7YGB)!&,@C/(S25;U&^GU74IKR;!EF;.%& /0 5Z;X(^%XECC
MU+7T.UANCM#QD>K_ .%)*YZE;$0H0YJGW'G^B^%]8U]\:?922(.LA^5!^)XK
MO=/^#%PP5M1U2./^\D*%OU./Y5ZY#!%;0K##&L<:#"JHP *DJN4\&KFE:;]S
M1'!P_"/PU&/F-Y(?]J4#^0%3'X5>%R,?9[CZ^<:[:BG9'&\77?VW]YY_<?"#
MP[(K>5+>Q,>A$@('X$5S=]\&+U%9K'5(9CV65"GZC->R4461I#'XB/VK^NI\
MT:MX-U_106O-.E$8_P"6D8WK^8Z?C6#7UH0",$ @]C7+Z]\/]!UX.\EL+:Y;
MGSX!M.?<=#4\IZ5'-NE6/S7^1\ZH[QNKHQ5U.0RG!!KVCX?_ !&&I^7I.LR!
M;SI#.>!+['_:_G7$^)?AKK&@[YX%^VV8_P"6D0^91[K7& LC@@E6!X/0@TMC
MOJ4Z.,IZ._GV/K2BO._AQX[_ +:A72=2D_XF$:_NY&/^N4?^S#]:]$K0^6K4
M949N$]PHHHH,@HHHH \V^.%P8O !B'2:YC!_ Y_I7S57T9\=_P#D2K?_ *^U
M_D:^<Z]3"_PSS\1\9W'PH\/6GB'QM!#?1>;;0(TS(>C$= ?;-?4D<:0QK'&B
MHBC"JHP /85\\? ;_D<+O_KU/\Q7T37+BF^>QT8=>Y<****Y3H"BBB@#SGXP
M^&;'5/!UUJA@47UB!(DJCYBN0"I]1@_I7S/7U[XZ /@76@?^?5Z^0N]>GA&W
M!HX,2DI)G6?#.X^S?$717[&?:?Q4BM3XS_\ )2;W_KE%_P"@"L'P%_R/FB?]
M?25O?&?_ )*3>_\ 7*+_ - %:/\ C+T(_P"77S//Z^HO@[_R373_ /?E_P#0
MS7R[7TS\+=0M-+^%%I>WLZ06\1E9W<X ^<UGB_@7J7A_B/0Y)$BC:21U1%&6
M9C@ >IKPCXD_%QKSS=&\-S%;?E9[Q>"_LGH/?O6%\1?BG=>*9'T[3&DMM(!P
M1T:?W;T'M7F]30PUO>F55KWTB!))))R36YX7\*:IXMU1;+3820.99FX2-?4G
M^E;'@3X=:EXSNQ)AK;3$/[VY9>O^ROJ:^E]!\/Z=X:TN/3],MUBA7DG^)SZL
M>YK2MB%#1;D4J+GJ]C)\%^!=+\&:>(K9!+>./W]TP^9SZ#T'M74T45Y<I.3N
MSO225D%%%%(9%=6L%[:R6UU$DT$JE7C<9##WKYW^)'PIG\/-+JVC(\^EDYDB
M'+P?XK[]J^C:1E5U*L RD8((R#6M*K*F[HSJ4U-69\15L>&_$VI^%=534-,G
M*..'0\K(OHP[UZE\2OA$8?.UKPW"3'RT]D@^[ZLGM[5XL002",$=0:]6$XU(
MZ'GRC*FSZR\$^/-,\:6&^W80WL8_?VK'YE]QZCWJ;QCXWTOP9IWGWC^9<N#Y
M-LA^>0_T'O7REIFJ7NC:A%?:?</!<Q'*NA_SD4NK:O?ZYJ,M_J-R]Q<R'YG8
M_H/05S?5%S7OH;_67R^9H>*O%NJ>+M4:]U&8E02(H5/R1+Z ?U[UA4JJSN%5
M2S,<  9)->Y?#7X1B(PZUXDAR_#P63#IZ,_O[5T3G&E$PC&521C?#;X2R:P8
MM8U^)H]/^]%;'AIO<^B_SKZ!AABMX4AAC6.)%"HBC 4#L!3P   !@"BO+J59
M5'=GH0IJ"LCP3]H"X8ZQI%MN.Q8'<KVR6QG]*\<KUOX^?\C/IW_7J?\ T*O)
M*].A_#1P5OC9[/\  GPU97KWVMW<*32V[B&!77(4D9+#W[5[O7DWP#_Y%;4?
M^OO_ -E%>LUYV(;=1G;124$%%%%8&P4444 >%?'3PM:68LM>L[=(6F<PW&P8
M#-C*G'KP:\6KZ0^.W_(@P_\ 7]'_ .@O7S?7K89MT]3SJZ2GH=+X4\2S>'TN
MA$VWSBI/X9_QHKFJ*T=.+=V9J;2LC[=9@JEF( '4FN&\2_$_2-%#P6)%_>#C
M$9^13[M_A5'Q?X2\8ZU<2);ZS%+8N<B GR@H]#@?-^-4/#?PA$4ZW&O3I(%.
M1;PDX/\ O-Z?2O$=SZ:C2PT8^TJSOY(YB&U\5?$K4!)*[?9E;!=LK#%]!W/Y
MFO4/#7P[T;P^J2O&+R\'6:49 /\ LKT%=3;6T%G;I;VT210H,*B#  J6A(BO
MC9U%R0]V/9!7D/QCUHM/::-$YP@\Z8 ]S]T'\.?QKUZOGKQ8)O$/Q)N;6(;F
M>Y%N@7T'R_TI2V-<L@G6YY;15SH/A9X-2]E_MW4(MT,38MXV'#-_>^@_G]*]
MEJKIUA#IFFV]C;KMB@0(H^E6J:5CEQ->5>HYOY>@5S6L^-=,TIVA0FZN!P4B
MZ*?<]*Q/&?BJ4SOI.G2%<<3RKU_W0?YUR=I8;L$BNRE037-,\^51WM$W[GX@
MZQ,^;6VMX4]&!<_TIL7C[7(Y TT-M*G=0A4G\<U7BTSY<[>*<VF@ID+D>HK?
MEI;6(]_N=/I7C_3[R017L;6<AX!8Y0_CV_&NM5E=0RL&4C((/!KQJZT[ /%:
MOA?Q--HMTEE>.6L7. 6/^J/J/:L:F'5KP+C4:TD>HT4@(90RD$$9!%5M0AEE
MM&-NP6X3YXB3QN'8^QZ5QFY:KA_%?PUTS7E>XL@ME?==RCY'/^T/ZBNLTO48
MM5TZ*[BX#C#)W1APRGW!R*N4-=&:4JLZ4N:#LSY@U#3-6\*ZNJ7$<EM=1,'C
M<=#CH5/>O>/!'BN+Q3HRR,0M[" MQ&/7^\/8UJZWH.G^(;!K/4(!(A^ZW\2'
MU![5XY-I>K_##Q-#?INGT]VVF11PZ'JK>AJ=CUY588ZGRO2HMO,]UHJO87L&
MI6$%[;/O@F0.A]C5BJ/%::=F%%%% CRWX[_\B5;?]?:_R-?.=?1GQW_Y$JV_
MZ^U_D:^<Z]7"_P ,\_$?&>J_ ;_D<+S_ *]#_,5]$U\[? ;_ )'"\_Z]#_,5
M]$UQXK^(=.'^ ****YC<**** .?\<_\ (C:U_P!>K_RKY![U]?>.?^1&UK_K
MU?\ E7R#7HX/X6<.)^)'1> O^1\T3_KZ2M[XS_\ )2;W_KE%_P"@"L'P%_R/
MFB?]?25O?&?_ )*3>_\ 7*+_ - %;O\ BKT,E_#?J>?UT.H3>(?^$0TJ*Y$B
MZ)N<VVW[C-N.[..^?6N>KZ6^&6E66M?"6TL-0MTGMI6E#(P_VSR/0^]%:?(E
M)H*4.=M'S35_1)=-AUBUDU:"2>P5QYT<;;6(KL/B#\,K[PA.UY:![K2'/RRX
M^:+_ &7_ ,:X"KC)3C=$.+B[,^RO#M[I%_H=M-H;0FPV 1K$,!?8CL:U*^1_
M!OC?5/!FHB>SD,ELY_?VS'Y)!_0^]?3?A;Q9I?B[2UO=.ER1Q+"Q^>(^A']>
M]>96HNF[]#T*5535NINT445SFP4444 %%%% !7D?Q+^$\&J1SZUH2)#>J"\U
MN.%FQR2/1OYUZY5>_P#^0==?]<7_ )&KISE"5T1.*DK,^*:=%&\TJ11J6=V"
MJ!W)IM7-(_Y#-C_U\1_^A"O;9Y1] _#?X4P>'ECU76D2?5" T<1Y6W_Q;W[5
MZC117B3FYN[/6C%15D%%%%04?/?Q\_Y&?3O^O4_^A5Y+7K7Q\_Y&?3O^O4_^
MA5Y+7L4/X:/,K?&SZ%^ ?_(JZC_U]_\ LHKUFO)O@'_R*NH_]??_ +**]9KS
M:_\ $9W4?@04445B:A1110!YE\=O^1!A_P"OZ/\ ]!>OFZOI'X[?\B##_P!?
MT?\ Z"]?-U>IA?X9Y^(^,****ZCG/MZBFR,4C9E4L0,[1WJ*TNX+ZV2XMW#Q
MOT(_45X)[!/1110 5XIX-M/M/Q:NWD&?)DFD^AR0/YU[77FWARU73_BYKD+8
MS-&94^C$'^M)G=A9\L*O^']3TFLW7]1.E:)=7:X+JN$&?XCP*TJY/XAL1X;5
M>S3KG\C6E-<TTF>?-VBV>>64332&1R2S'))[FG>*/$=MX0T3[7(@EN93LMX?
M[S>I]A5K3%'%>6?&&XD?Q7;V[,?*BMEVKVR2<FNZO-I:&%-'*ZOXJUO6[EI[
MW4)CGI'&Q5%'H *KV.NZMIMPL]GJ-S%(IR,2$C\C6?17!=G0?5WA@6^N_#VQ
MU:YO(9=0E@$D@C( W=UV^M8>HVV,\5XI\/;N:U\=:1Y;-MDG$;*#U5NM>]:D
MH^:NRA)]3&HD=AX&U-K_ $$0RMNEMF\LD_W>WZ5T]>??#EB+O44[;4/ZFO0:
MYJR2FTC2F[Q1QVC7(TOQ]J^B9VP72K?0+Z,>)/S/-=C7F7C"\33?BQX=N6)"
MM$(WQW!9A_6O3:=6.D9=U_P!0>K79A5:_L+;4[*6SO(5E@D&&5JLT5B:IM.Z
M.'\.VUQX,UDZ'<.TFE7C%[&8_P #]XSZ$CD?3WKN*KWME#?VK6\XRIY!'52.
MA![$&I8E=(D5VW,!@MZT&E2I[1\SWZ_YCZ***#(\S^.4+2> UD XCND)_'(K
MYMKZ^\;Z'_PD7@[4M-5=TLD1:(?[:\K^HKY#EC>&5XI$*2(2K*PP01U%>GA)
M7A8X,2O>N>A?!?5(-.\>1QW$JQK=0M$I8X!;J!^-?35?$2LR,&5BK Y!!P0:
MZRS^)WC*RC6.+79V11@"15?]2":*^'=27,F%*LH*S/K&BOEO_A;_ (T_Z"B_
M]^4_PH_X6_XT_P"@HO\ WY3_  KG^J3[HV^LP/J2BOEO_A;_ (T_Z"B_]^4_
MPIDGQ;\:R+@:P4]UA3/\J/JD^Z#ZS ]R^*^JPZ9\/M15Y566Z40Q*3RQ)&?T
MS7RM6EJ^OZMK]PL^JW\UW(HPID;A?H.@K-KMHTO9QL<M6ISNYU7PW@-Q\0]%
M0?\ /QN_($_TK6^,_P#R4F]_ZY1?^@"M;X&^'I+[Q/+K,D;?9[&,JC8X,C<8
M_ 9_,5D_&?\ Y*3>_P#7*+_T 5/->O;LBK6I7\SS^OJ+X._\DUT__?E_]#-?
M+M?47P=_Y)KI_P#OR_\ H9J,7\'S*PWQG<3P17,#P3QK)$XVLCC(8>A%> ?$
MCX22Z09=7\/Q/+8<M+;#EH?<>J_RKZ#H(R,'I7#3JRINZ.N=-35F?$-:OA_Q
M#J7AG5(]0TR<Q2K]X?PN/1AW%>R_$GX1)>^=K/AR$)<8+36:C D]2GH?:O!Y
M(WAE:.1&1T)5E88((Z@UZD)QJQT//G"5-GU9X%^(.F^-+(!"MOJ,8_?6K'GZ
MKZBNPKXIL;^ZTR]BO+*=X+B([DD0X(-?1OPY^*=KXHCCTW5&2WU=1@=EG]U]
M#[?E7#7P[C[T=CKI5N;26YZ31117(=(4444 %5]0_P"0;=?]<7_D:L57U#_D
M&W7_ %Q?^1IK<&?%-7-(_P"0S8_]?$?_ *$*IU<TC_D,V/\ U\1_^A"O=9Y"
MW/M*BBBO!/7"BBB@#P']H"(KKVDRXX:V89^C?_7KQ^OI#XW:#+JGA&._MX]\
MEA)YCX'/ED8/X#@U\WUZV&E>FO(\VNK39[M\ =4MOL.J:6T@%SYJS*A_B7&#
MC\:]HKXILKZZTZ[2ZLKB2WG0Y62-BI%=9#\5_&L(Q_;<CC_;B0_^RUE5PSE+
MFBS6G748V9]545\M_P#"W_&G_047_ORG^%'_  M_QI_T%%_[\I_A6/U2?=&G
MUF!]245\M_\ "W_&G_047_ORG^%0S_%?QK."/[;D0'^Y$@_I1]4GW0?68GHW
MQ\UJ)-+T[14=6FDE-Q(H/*@ @9^NX_E7@M6+V^NM1NWNKVXDGGD.6DD8L35>
MN^E3Y(\IR5)\\KFUH6@SZTLYA0MY17.!ZY_PHKVCX)>%_)\,7.IWD9_TZ4>4
MI'\"9&?Q)/Y45RU,3RR:1T0H7BFSURN'UN_F\$:X-3V-)H=^X%TB_P#+"7^^
MOL>X]J[BJ>J:;;:QIEQ87:!X9D*D>GN/<5QTY)/WMCJDFUIN3VMU!>VL=S;2
MK+!*H9'0Y#"I:\+TOQ!JOPS\13:/?AY].WYV?[)Z.G]17M&EZK9:S81WMA.L
MT#CAE/0^A]#5UJ#IZK5/9D4ZJGILUT+E<=K5H-.\?Z-K*KB.Y#6<S=@2/ES_
M "_"NQJCK&F1ZOIDMG)QNPR-_=8'(/YU@=5*?++79Z?>7JYSQQ:M=>&)RO6)
MED_+C^M;.GW#W%FAF 6=?DE4=F'7_'\:L2QK-$\;C*."K#U!JHRY9)F,HW31
MXSILH&*Y#XM>&Y;ZUM]>M(VD:W3RKE5YPF<AL?B<_A7::QI<WA[6'MW!\ECN
MA<_Q+5JUO%9-K892,$'D$5Z%2*G&Z.:#L[,^8**]XU;X7>&]6N&N+=IK"1^6
M6'!3/J%/2J]A\(O#UG.LMW=W-Z%.?+;"*?KCM7'[*1OS(Y7X2^&YKW7!KDR%
M;.RSY;$??D/3'TKU;49AS4YDMK*U2VM8DA@C&$C08"BLQ(KC5K^.SMEW22-@
M>@'<GVKKI0Y5J93E<['X=6C+:WEZPPLKA%]\=?YUV]4]+T^+2M-@LX1\L:X)
M_O'N?Q-6)YH[:"2>9PD<:EF8G@ =:XJDN>;9M%<L;'C'Q*N_-^)6F1*?FMQ"
MOXE]W]:]K'2OG*TN9?%GQ,@N"Y_TB]#KN[(IR!_WR *^C:ZL7'DC"'5(Y\.^
M9SEW84445PG4%%5KO4;*P4->7<, )P#*X7/YU+#/%<1B2&5)$89#(P((IV D
MHHHI %>8>/?A#:^);F34])E2SU!\F1&'[N8^I]#[UZ?15PG*#O$F45)69\G:
MG\,_%VE%C-H\TD:]9(,.OZ5@-HNJH<-IEX#[P-_A7VA174L9+JCG>&71GQ;_
M &1J7_0/N_\ ORW^%']D:E_T#[O_ +\M_A7VC@>@HP/04_KC["^JKN?%W]D:
ME_T#[O\ [\M_A2C1]3/33KO_ +\M_A7VA@>@I<8H^N/L'U5=SXZL?"7B'49/
M+M-&O9&_ZXD?SKN?#GP0UW49T?6'33K7JPR&D/L .!^-?1E%3+%S>RL5'#16
MYG:%H=AX=TF'3=-A$5O$/Q8]R3W)KYZ^,.GWMQ\1;QX;2>1/*B^9(R1]P=P*
M^EJ,#TK&G5<)<VYI4IJ<>4^+?[(U+_H'W?\ WY;_  KZ9^$4,L'PYL(YHWC<
M/)E74@CYSV-=Q@>@I:NKB/:1M8FG1Y'>X4445S&X5YQ\1/A;:>*HWU'30EMJ
MZC)/1)_9O?WKT<D 9- ((R#FJA-P=T3**DK,^,[KP_K%E=RVUQIETDL3%77R
MF.#]14<>F:K%(LD=C>(ZG*LL3 @_E7VA@>E)@>@KL^N/L<WU9=SR7X<?$B_N
M!#HWB6UNEFX2"\:%L/Z!^.OO7K=)@>@I:Y)R4G=*QTP32LW<****@H*KWX)T
MZY &28GX_ U8HH ^+?[)U+_H'W7_ 'Y;_"KFE:5J*ZQ9,UA= "XC))A;^\/:
MOL7 ]!1@>@KN^N/L<GU9=Q:*0D#J0*6N$ZPHHHH ;)&DT31R('1P596&00>U
M>)>,?@=))<R7OAF5 CG)LY3C;Z[6]/8U[?16E.I*#O$B<(S5F?(>H^ _%&E9
M-UHMV%_O(F\'\LUE'1]3'73KL?6!O\*^T,C.,C/I2UU+&/JCG>&71GQ;_9&I
M?] ^[_[\M_A1_9&I?] ^[_[\M_A7VC@>@HP/04?7'V#ZJNY\7?V1J7_0/N_^
M_+?X4HT?4STTZ[/T@;_"OM# ]!0"N< C/I1]<?8/JJ[GR'IW@;Q/JI'V31;M
MA_>:/8!^>*](\(_ VX-Q'=^)9D2)3G[)"V2_^\W8>PKW6BLYXJ<E9:%QP\5J
M]2.&&*V@C@AC6.*-0J(HP% Z 45)17*= 4444 <=\0?!Z^*-'\RW0#4;8%H6
M_OCNA/\ +WKQ+0O$>K>$M3:2TD9"K;9H'^Z^.Q']:^GJ\J^)W@,W2R:]I469
ME&;F%1]\?W@/7UKT,)77\*ILSCQ%)_Q(;HZKPKX^TGQ/&L2N+:^Q\UO(>I_V
M3W_G75U\CH[Q.'1BKJ<@@X(KT3PQ\6=1TL);:LIOK8<"3.)%'U[_ (UI7P#6
MM/[B*6,3TF>YA0"2 ,GJ:6L31/%NB^((P;"]C:3&3"QVNOU!K;KS)1<79H[D
MTU=%#5]'M-:LC;7:9'57'WD/J#7FVJ>%=6T5V>-#=6P/$D8R?Q'6O6**TIU9
M0VV)E!2/$UU!XSM?<K#@@\8I6U(D8!->Q3Z?9W/^NM89/]Y :;#I=A;G,5G
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M7DU\=*7NT]$>E2PBCK/5D5M;06=ND%M$D42#"H@P *EHHKSCM"BBB@ HHHH
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M /[^#_"C_A1/AC_GXO\ _OX/\*SYJ%^;6Y=JMK:'@&EZI<:+J]OJ%C(4FMY
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!V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
